Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 0.7 %

NYSE:BTX opened at $6.72 on Thursday. The company has a market capitalization of $395.31 million, a PE ratio of -2.96 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $6.57 and a 52-week high of $8.31. The stock has a fifty day simple moving average of $2.01 and a 200-day simple moving average of $1.35.

Brooklyn ImmunoTherapeutics Dividend Announcement

The company also recently declared a monthly dividend, which will be paid on Monday, March 31st. Stockholders of record on Friday, March 14th will be paid a dividend of $0.0862 per share. This represents a $1.03 annualized dividend and a dividend yield of 15.38%. The ex-dividend date is Friday, March 14th. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is presently -40.09%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.